Palbociclib

Where the papers sit

13 papers from the last 6 months study palbociclib directly · updated from PubMed 3 Oct 2026

• CDK4/6 Inhibition in Breast Cancer

  CDK4/6 inhibitor use in metastatic breast cancer is being defined by real-world treatment patterns, safety, age-related comorbidity and survival. Combination strategies add ipatasertib to endocrine therapy or CSF1R blockade to counter treatment-associated immunosuppression. Biomarker work links metastasis in triple-negative disease to a targetable miR-342-E2F network. The field is moving toward more individualized combinations and immune-aware treatment selection.

  6 papers · 46.2%

• CDK4/6 Inhibitor Development

  CDK4/6 inhibition is expanding beyond established breast cancer use into dedifferentiated liposarcoma, esophageal squamous cell carcinoma and meningioma. Palbociclib is being tested with retifanlimab, while subtype-specific vulnerabilities and immune-cell responses are defining new combination opportunities. Abemaciclib and palbociclib show divergent neuropsychiatric and systemic toxicity profiles, keeping comparative safety important. Drug-delivery platforms and microfluidic systems support efforts to improve exposure and model immune infiltration.

  5 papers · 38.5%

• Others — Drug and Infection Research

  Host-directed therapy for tuberculous meningitis uses ubenimex, imatinib and antibiotics across mouse and human models, while a separate study models pH-mediated drug interactions for formulation design. The shared thread is pharmacological optimization rather than one disease or mechanism. Evidence spans neuroinflammation, interferon responses and PBPK predictions. No single therapeutic direction unites the cluster.

  2 papers · 15.4%